
David Masson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7990899/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis. , 2022, 236, 108105.		13
2	The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease. Current Opinion in Lipidology, 2022, 33, 193-198.	2.7	13
3	Cholesterol and HIF-1α: Dangerous Liaisons in Atherosclerosis. Frontiers in Immunology, 2022, 13, 868958.	4.8	15
4	Alveolar SARS-CoV-2 Viral Load Is Tightly Correlated With Severity in COVID-19 ARDS. Clinical Infectious Diseases, 2021, 72, e446-e447.	5.8	22
5	Regulation of glycolytic genes in human macrophages by oxysterols: a potential role for liver X receptors. British Journal of Pharmacology, 2021, 178, 3124-3139.	5.4	9
6	Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Archives of Cardiovascular Diseases, 2021, 114, 132-139.	1.6	39
7	Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits. Atherosclerosis, 2021, 320, 10-18.	0.8	10
8	Non-lipogenic ABCA1 inducers: The holy grail in cardio-metabolic diseases?. EBioMedicine, 2021, 66, 103324.	6.1	1
9	High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia. Scientific Reports, 2021, 11, 10824.	3.3	17
10	Intra-Abdominal Lipopolysaccharide Clearance and Inactivation in Peritonitis: Key Roles for Lipoproteins and the Phospholipid Transfer Protein. Frontiers in Immunology, 2021, 12, 622935.	4.8	6
11	Muricholic Acids Promote Resistance to Hypercholesterolemia in Cholesterol-Fed Mice. International Journal of Molecular Sciences, 2021, 22, 7163.	4.1	6
12	Brown adipose tissue monocytes support tissue expansion. Nature Communications, 2021, 12, 5255.	12.8	23
13	Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet. Journal of Lipid Research, 2021, 62, 100013.	4.2	11
14	Increased Phospholipid Transfer Protein Activity Is Associated With Markers of Enhanced Lipopolysaccharide Clearance in Human During Cardiopulmonary Bypass. Frontiers in Cardiovascular Medicine, 2021, 8, 756269.	2.4	3
15	Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity. Nature Immunology, 2021, 22, 1403-1415.	14.5	72
16	Interplay between Liver X Receptor and Hypoxia Inducible Factor 1α Potentiates Interleukin-1β Production in Human Macrophages. Cell Reports, 2020, 31, 107665.	6.4	39
17	LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients. Journal of Lipid Research, 2020, 61, 1776-1783.	4.2	4
18	CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS. Critical Care, 2020, 24, 632.	5.8	67

#	Article	IF	CITATIONS
19	Inhibition of mitophagy drives macrophage activation and antibacterial defense during sepsis. Journal of Clinical Investigation, 2020, 130, 5858-5874.	8.2	87
20	Glucocorticoids impair HDL-mediated cholesterol efflux besides increased HDL cholesterol concentration: a proof of concept. European Journal of Endocrinology, 2020, 183, 297-306.	3.7	6
21	Revisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis. International Journal of Molecular Sciences, 2019, 20, 3787.	4.1	18
22	Macrophage fatty acid metabolism and atherosclerosis: The rise of PUFAs. Atherosclerosis, 2019, 291, 52-61.	0.8	37
23	Improved quantification of plasma lipopolysaccharide (LPS) burden in sepsis using 3-hydroxy myristate (3HM): a cohort study. Intensive Care Medicine, 2019, 45, 1678-1680.	8.2	13
24	End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation. Frontiers in Immunology, 2019, 10, 1630.	4.8	24
25	Polysaccharide Chain Length of Lipopolysaccharides From Salmonella Minnesota Is a Determinant of Aggregate Stability, Plasma Residence Time and Proinflammatory Propensity in vivo. Frontiers in Microbiology, 2019, 10, 1774.	3.5	20
26	Healthy adiposity and extended lifespan in obese mice fed a diet supplemented with a polyphenol-rich plant extract. Scientific Reports, 2019, 9, 9134.	3.3	25
27	Fatty acids getting NAD+ about cardiometabolic diseases. Current Opinion in Lipidology, 2019, 30, 486-487.	2.7	0
28	Fructose and glucose can regulate mammalian target of rapamycin complex 1 and lipogenic gene expression via distinct pathways. Journal of Biological Chemistry, 2018, 293, 2006-2014.	3.4	12
29	LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis. Atherosclerosis, 2018, 275, 409-418.	0.8	31
30	Fatty acid metabolism in macrophages: a target in cardio-metabolic diseases. Current Opinion in Lipidology, 2017, 28, 19-26.	2.7	30
31	Fatty acids and macrophage functions. Current Opinion in Lipidology, 2017, 28, 443-444.	2.7	0
32	Recombinant human plasma phospholipid transfer protein (PLTP) to prevent bacterial growth and to treat sepsis. Scientific Reports, 2017, 7, 3053.	3.3	26
33	LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood, 2016, 128, 2694-2707.	1.4	50
34	Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients. Atherosclerosis, 2016, 251, 339-347.	0.8	17
35	Insulin Dissociates the Effects of Liver X Receptor on Lipogenesis, Endoplasmic Reticulum Stress, and Inflammation. Journal of Biological Chemistry, 2016, 291, 1115-1122.	3.4	16
36	Diagnostic Accuracy of Inflammatory Markers As Early Predictors of Infection After Elective Colorectal Surgery. Annals of Surgery, 2016, 263, 961-966.	4.2	104

#	Article	IF	CITATIONS
37	The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation. Haematologica, 2016, 101, e72-e76.	3.5	30
38	The potential of cholesteryl ester transfer protein as a therapeutic target. Expert Opinion on Therapeutic Targets, 2016, 20, 47-59.	3.4	8
39	GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetologica, 2016, 53, 237-242.	2.5	17
40	Extreme hyperferritinemia in the setting of acute myeloid leukaemia: a case report of hemophagocytic lymphohistiocytosis. Biochemia Medica, 2016, 26, 255-259.	2.7	3
41	Are Adiponectin and Leptin Good Predictors of Surgical Infection after Colorectal Surgery? A Prospective Study. Surgical Infections, 2015, 16, 566-571.	1.4	5
42	Liver X Receptor Activation Promotes Polyunsaturated Fatty Acid Synthesis in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1357-1365.	2.4	52
43	Insulin response dysregulation explains abnormal fat storage and increased risk of diabetes mellitus type 2 in Cohen Syndrome. Human Molecular Genetics, 2015, 24, 6603-6613.	2.9	26
44	Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2015, 126, 4933-4933.	1.4	0
45	Low Preoperative Cholesterol Level Is a Risk Factor of Sepsis and Poor Clinical Outcome in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass*. Critical Care Medicine, 2014, 42, 1065-1073.	0.9	49
46	Biological activities of Schottenol and Spinasterol, two natural phytosterols present in argan oil and in cactus pear seed oil, on murine miroglial BV2 cells. Biochemical and Biophysical Research Communications, 2014, 446, 798-804.	2.1	50
47	The authors reply. Critical Care Medicine, 2014, 42, e686-e687.	0.9	2
48	Activation of liver x receptors promotes polyunsaturated fatty acid synthesis and eicosanoid secretion in human macrophages. Atherosclerosis, 2014, 235, e49.	0.8	0
49	Biological activities of the LXRα and β agonist, 4β-hydroxycholesterol, and of its isomer, 4α-hydroxycholesterol, on oligodendrocytes: Effects on cell growth and viability, oxidative and inflammatory status. Biochimie, 2013, 95, 518-530.	2.6	22
50	Development of Abdominal Aortic Aneurysm Is Decreased in Mice with Plasma Phospholipid Transfer Protein Deficiency. American Journal of Pathology, 2013, 183, 975-986.	3.8	20
51	Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: Lack of compensation by LXRβ activation. Biochemical Pharmacology, 2013, 86, 122-129.	4.4	48
52	Liver X Receptor Regulates Arachidonic Acid Distribution and Eicosanoid Release in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1171-1179.	2.4	54
53	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genetics, 2012, 8, e1002607.	3.5	419
54	Intravoxel Incoherent Motion Diffusion-weighted Imaging in Nonalcoholic Fatty Liver Disease: A 3.0-T MR Study. Radiology, 2012, 265, 96-103.	7.3	148

#	Article	IF	CITATIONS
55	Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity, 2012, 36, 362-373.	14.3	275
56	Identification of Biological Markers of Liver X Receptor (LXR) Activation at the Cell Surface of Human Monocytes. PLoS ONE, 2012, 7, e48738.	2.5	12
57	Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. European Radiology, 2012, 22, 855-863.	4.5	29
58	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011, 43, 1131-1138.	21.4	501
59	Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice. Journal of Hepatology, 2011, 55, 154-161.	3.7	39
60	PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver International, 2011, 31, 1332-1336.	3.9	25
61	Liver methylene fraction by dual―and tripleâ€echo gradientâ€echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness after SPIO administration. Journal of Magnetic Resonance Imaging, 2011, 33, 119-127.	3.4	12
62	Lack of an association between an apolipoprotein C3 genetic variant and the liver fat content in patients with type 2 diabetes. Hepatology, 2011, 54, 1109-1110.	7.3	2
63	Constitutive Androstane Receptor Activation Decreases Plasma Apolipoprotein B–Containing Lipoproteins and Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2232-2239.	2.4	31
64	Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 766-774.	2.4	41
65	Câ€Reactive Protein Is an Early Predictor of Septic Complications After Elective Colorectal Surgery. World Journal of Surgery, 2010, 34, 808-814.	1.6	176
66	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	27.8	3,249
67	Reduced VLDL clearance in ApoeNpc1 mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels. Journal of Lipid Research, 2010, 51, 2655-2663.	4.2	10
68	Specifically PNPLA3-Mediated Accumulation of Liver Fat in Obese Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E430-E436.	3.6	39
69	Human luteinized granulosa cells secrete apoB100-containing lipoproteins. Journal of Lipid Research, 2010, 51, 2245-2252.	4.2	37
70	Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI Inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2054-2060.	2.4	75
71	Liver X Receptor–Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1923-1929.	2.4	21
72	Induction of Transglutaminase 2 by a Liver X Receptor/Retinoic Acid Receptor α Pathway Increases the Clearance of Apoptotic Cells by Human Macrophages. Circulation Research, 2009, 105, 393-401.	4.5	96

#	Article	IF	CITATIONS
73	Quantification of Liver Fat Content: Comparison of Triple-Echo Chemical Shift Gradient-Echo Imaging and in Vivo Proton MR Spectroscopy. Radiology, 2009, 250, 95-102.	7.3	170
74	The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. Journal of Lipid Research, 2009, 50, S201-S206.	4.2	109
75	Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma. Journal of Lipid Research, 2009, 50, 1842-1851.	4.2	25
76	Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy. European Radiology, 2009, 19, 1786-1793.	4.5	49
77	Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. Current Opinion in Investigational Drugs, 2009, 10, 980-7.	2.3	9
78	Effect of Plasma Phospholipid Transfer Protein Deficiency on Lethal Endotoxemia in Mice. Journal of Biological Chemistry, 2008, 283, 18702-18710.	3.4	58
79	Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. Journal of Lipid Research, 2008, 49, 1682-1691.	4.2	37
80	Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney International, 2007, 72, 871-878.	5.2	39
81	Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. Molecular Human Reproduction, 2007, 13, 373-379.	2.8	37
82	Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein. Journal of Lipid Research, 2007, 48, 30-40.	4.2	24
83	High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 1948-1955.	2.8	56
84	Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients. Molecular Genetics and Metabolism, 2006, 88, 196-198.	1.1	20
85	α-Tocopherol Modulates Phosphatidylserine Externalization in Erythrocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2160-2167.	2.4	35
86	Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes. Journal of Lipid Research, 2006, 47, 356-365.	4.2	6
87	Phospholipid transfer protein (PLTP) deficiency reduces sperm motility and impairs fertility of mouse males FASEB Journal, 2006, 20, 794-796.	0.5	19
88	Myocardial Injury in Critically III Patients. Chest, 2005, 128, 2758-2764.	0.8	83
89	Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. Biochemical Journal, 2005, 385, 189-195.	3.7	19
90	Expression of the Pregnane X Receptor in Mice Antagonizes the Cholic Acid–Mediated Changes in Plasma Lipoprotein Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2164-2169.	2.4	37

#	Article	IF	CITATIONS
91	Caspase-2, a Novel Lipid Sensor under the Control of Sterol Regulatory Element Binding Protein 2. Molecular and Cellular Biology, 2005, 25, 9621-9631.	2.3	46
92	Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI. Journal of Biological Chemistry, 2005, 280, 38108-38116.	3.4	45
93	Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice FASEB Journal, 2005, 19, 1-16.	0.5	106
94	Effect of cholesteryl ester transfer protein (CETP) expression on diet-induced hyperlipidemias in transgenic rats. Atherosclerosis, 2005, 178, 279-286.	0.8	15
95	Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. Journal of Lipid Research, 2004, 45, 543-550.	4.2	44
96	Alterations in Plasma Vitamin E Distribution in Type 2 Diabetic Patients With Elevated Plasma Phospholipid Transfer Protein Activity. Diabetes, 2004, 53, 2633-2639.	0.6	34
97	Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. European Journal of Clinical Investigation, 2004, 34, 569-575.	3.4	22
98	Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short-term hypothyroidism Lack of relationship to lipoprotein abnormalities. Clinical Endocrinology, 2003, 58, 581-588.	2.4	11
99	Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. Journal of Lipid Research, 2003, 44, 1453-1461.	4.2	64
100	Human seminal plasma displays significant phospholipid transfer activity due to the presence of active phospholipid transfer protein. Molecular Human Reproduction, 2003, 9, 457-464.	2.8	24
101	Apolipoprotein Cl Deficiency Markedly Augments Plasma Lipoprotein Changes Mediated by Human Cholesteryl Ester Transfer Protein (CETP) in CETP Transgenic/ApoCl-knocked Out Mice. Journal of Biological Chemistry, 2002, 277, 31354-31363.	3.4	46
102	Expression of simian CETP in normolipidemic Fisher rats has a profound effect on large sized apoE-containing HDL. Journal of Lipid Research, 2002, 43, 2164-2171.	4.2	18
103	Prevention of LDL \hat{l} ±-tocopherol consumption, cholesterol oxidation, and vascular endothelium dysfunction by polyphenolic compounds from red wine. Atherosclerosis, 2002, 165, 41-50.	0.8	29
104	La protéine plasmatique de transfert des phospholipides (PLTP) : un nouveau facteur athérogène. Medecine/Sciences, 2002, 18, 398-400.	0.2	0
105	The impairment of endothelium-dependent arterial relaxation by7-ketocholesterol is associated with an early activation of protein kinase C. British Journal of Pharmacology, 2002, 137, 655-662.	5.4	19
106	Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate. Journal of Biological Chemistry, 2001, 276, 25841-25847.	3.4	84
107	Human Apolipoprotein C-I Accounts for the Ability of Plasma High Density Lipoproteins to Inhibit the Cholesteryl Ester Transfer Protein Activity. Journal of Biological Chemistry, 2000, 275, 37504-37509.	3.4	113
108	Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering αâ€ŧocopherol to endothelial cells. FASEB Journal, 1999, 13, 883-892.	0.5	80

#	Article	IF	CITATIONS
109	Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein. Journal of Lipid Research, 1998, 39, 131-142.	4.2	30
110	Structure and function of the plasma phospholipid transfer protein. Current Opinion in Lipidology, 1998, 9, 203-209.	2.7	63
111	Differential Interaction of the Human Cholesteryl Ester Transfer Protein with Plasma High Density Lipoproteins (HDLs) from Humans, Control Mice, and Transgenic Mice to Human HDL Apolipoproteins. Journal of Biological Chemistry, 1997, 272, 24287-24293.	3.4	12
112	4.W25.3 Interaction of the cholesteryl ester transfer protein with high density lipoproteins from human and mouse plasmas. Atherosclerosis, 1997, 134, 294.	0.8	0
113	Role of Lipoprotein-Bound NEFAs in Enhancing the Specific Activity of Plasma CETP in the Nephrotic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2559-2567.	2.4	28